CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S, La Pietra V, Piccarducci R, Pietrobono D, Cavallini C, D'Amore VM, Cerofolini L, Giuntini S, Russomanno P, Puxeddu M, Nalli M, Pedrini M, Fragai M, Luchinat C, Novellino E, Taliani S, La Regina G, Silvestri R, Martini C, Marinelli L.
Daniele S, et al. Among authors: la pietra v, la regina g.
Eur J Pharmacol. 2021 Apr 15;897:173936. doi: 10.1016/j.ejphar.2021.173936. Epub 2021 Feb 10.
Eur J Pharmacol. 2021.
PMID: 33581134